

Aerpio Therapeutics to Present TIME-2 Phase 2a Study of AKB-9778 in Diabetic Macular Edema Data at 2015 American Academy of Ophthalmology Annual Meeting Retina Subspecialty Day

CINCINNATI--(BUSINESS WIRE)--Aerpio Therapeutics, Inc., a biopharmaceutical company focused on advancing first-in-class treatments for the eye, today announced that data from the TIME-2 Phase 2a Study of AKB-9778 in the treatment of patients with diabetic macular edema (DME) will be presented at the upcoming American Academy of Ophthalmology (AAO) Annual Meeting's Retina Subspecialty Day.

In July, the company announced data showing that a combination of AKB-9778 and Lucentis® provided significant benefit over Lucentis® monotherapy in reduction of macular edema with a trend towards improved visual acuity at the end of a 3-month treatment period. The presentation will provide further information on these results, as well as other findings from the TIME-2 study. AAO is taking place in Las Vegas, Nevada from November 13, 2015 to November 17, 2015. TIME-2 will be presented at 11:41 AM on November 13, 2015.

About Aerpio Therapeutics

Aerpio Therapeutics, Inc., a clinical-stage biopharmaceutical company focused on the development of novel therapies for vascular disorders with a focus on diseases of the eye. Aerpio is a leader in the development of small molecule drugs based on Tie2 activation. The Company's lead program, AKB-9778, is a first-in-class stabilizer of the Tie2 pathway and is in clinical development for diabetic eye disease and retinal vein occlusion. More information is available at www.aerpio.com.

Contacts

Aerpio Therapeutics, Inc.
Dhaval Desai
Vice President of Medical Affairs
d-desai@erpio.com

or

Burns McClellan on behalf of Aerpio Therapeutics
Justin Jackson, 212-213-0006
jjackson@burnsmc.com